Acusensus FY26 Investor Presentation
| Stock | Acusensus Ltd (ACE.ASX) |
|---|---|
| Release Time | 25 Aug 2026, 8:33 a.m. |
| Price Sensitive | Yes |
Acusensus FY26 Investor Presentation
- Record revenue growth of $27m to $86m
- Adjusted EBITDA above top-end of guidance
- 8x increase in international gross profit
- FY27 set to surpass $100m of revenue
- Well funded, with $26m of cash
Acusensus Ltd presented its full-year FY26 results, highlighting significant achievements and future growth potential. Key highlights include a record revenue growth of $27m to $86m, surpassing guidance, and an 8x increase in international gross profit. The company is well-funded with $26m in cash, and FY27 is set to surpass $100m in revenue. The presentation detailed operational highlights such as a 47% increase in revenue-generating units and a 27% international revenue share. Financial highlights include a 42.0% gross profit margin and $8.5m in Adjusted EBITDA, up 49% compared to the prior comparable period. The company also announced new contract wins, expansions, and upgrades across Australia and internationally, with a total contract value of $494m. The outlook for future growth remains positive, with a strong pipeline of potential opportunities and continued investment in sales and R&D.
FY27 revenue set to surpass $100m
Continued investment in sales and R&D to pursue a growing pipeline of potential opportunities and drive future value creation through new innovations.